A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, has launched Global Access Health (GAH), a social enterprise that will seek to expand access to affordable state-of-the-art medical technology through decentralized research, development, and manufacturing in and for the Global […]
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures singleand multi-organ microphysiological systems (MPS), has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
Biotium, a leading provider of reagents for immunofluorescence microscopy, is significantly expanding its line of antifade wet-set and hardset EverBrite Mounting
German independent research institute BioMed X has started two new research projects with Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies.
All start-ups that want to participate in this year’s 10th MEDICA Start-up Competition by submitting innovations can send in their application free of charge until 22 September 2021. For more information about the competition, visit: https://www.medica-tradefair.com/mac2
In addition to these highlights, a programme of several on-stage events at the epicentre of the trade fair will also be on offer. Holders of the relevant tickets can follow the talks and discussions simultaneously via livestreams on the industry portals MEDICA.de and COMPAMED.de.
The event organisers say decision-makers of the healthcare industry have committed to participating on site. In a recent survey of several thousand MEDICA and COMPAMED visitors from previous years, three quarters stated that they intend to attend this year’s trade fairs.
Pharmacokinetic and immunogenicity projects can be both diverse and complex, involving work packages from antibody generation and production to the analysis of clinical samples with validated assays.
In an effort to simplify the process, BioGenes and FyoniBio has signed an agreement under wich they will cooperate to provide a single source for these services.
BioGenes, as an expert in antibody production and ELISA setup, takes care of the first steps of the project, while FyoniBio, a specialist in bioassay development and validation for analysis of clinical samples, uses their expertise to transfer the assay to the MSD2 platform for analysing clinical samples under “good clinical and laboratory practice” (GCLP). Specialists at the Berlin-based companies guarantee comprehensive project management.
“We are very pleased that the cooperation with FyoniBio has now officially started,” said Dr. Alexander Knoll, CEO of BioGenes GmbH. “We are convinced that our complete package for high-quality and customized immunological tests for new biological compounds and clinical samples offers an enormous added value for customers.”
“Both companies want to provide the perfect service for each customer. In this respect, as well as regarding scientific excellence in their respective fields, the two companies complement each other very well,” added Dr. Hans Baumeister, Service Division Manager at FyoniBio. “We are looking forward to the first joint projects.”
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
